Next-Generation Sequencing (NGS) Market worth 10,371.1 M USD by 2021

Friday 11 March 2016, Amsterdam

The report, now available on ASDReports, "Next-Generation Sequencing (NGS) Marketby Platforms (HiSeq, MiSeq, HiSeq X Ten/X Five, Nextseq500, Ion Proton, PGM, IonS5, PacBio & Sequel), Services (Targeted Sequencing, De novo), & Application (Diagnostic, Drug Discovery) - Global Forecasts to 2021", The NGS market is expected to reach USD 10,371.1 Million by 2021 from USD 4,031.7 Million in 2016, at a CAGR of 20.8%.

The report provides a detailed overview of the current trends and major drivers, restraints, opportunities, and challenges impacting the global NGS market along with the estimates and forecasts of the revenue and market share analysis.

The global NGS market is poised to witness rapid growth between 2016 and 2021. Technological advancements in NGS products, increasing applications of NGS, entry of new market players, growing partnerships & collaborations among market players, and growing incidences of cancer, inherited rare disorders, and pre- and neo-natal disorders will majorly drive the NGS market.

This report broadly segments the global NGS market into products & services, technology, application, and end user. The NGS market, by products & services is segmented into pre-sequencing products & services, NGS platforms, consumables, sequencing services, data analysis/bioinformatics. The pre-sequencing products & services segment if further categorized into DNA fragmentation. End repair, A-tailing, & size selection; library preparation & target enrichment; and quality control. The NGS platforms segment is sub-segmented into HiSeq Series, MiSeq Series, HiSeq X Ten & X Five, NextSeq500, Ion PGM, ION Proton, Ion S5 & S5 XL, PacBioRS II, and Sequel System. Based on applications, the sequencing services market is segmented into targeted sequencing, whole-genome sequencing, exome sequencing, RNA-Seq, De novo sequencing, Methyl-Seq, and ChiP-seq.

On the basis of technology, the global NGS market is segmented into sequencing by synthesis (SBS), ion semiconductor sequencing, sequencing by ligation (SBL), pyrosequencing, and single-molecule real-time (SMRT) sequencing. In 2016, the SBS technology is expected to account for the largest share of the global NGS market, by technology.

Based on application, the global NGS market is segmented into diagnostics, drug discovery, biomarker discovery, personalized medicine, agriculture & animal research, and others (marine, forensic, & biofuel research). In 2016, the diagnostics application segment is expected to account for the largest share of the NGS market, by application.

The end users of NGS market include research centers & academic/government institutes, hospitals & clinics, pharmaceutical & biotechnology companies, and others (non-profit organizations & agrigenomics organizations). In 2016, the research centers & academic/government institutes end user segment is expected to account for the largest share of the NGS market, by end user.

This report covers the NGS market across four major geographies, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America is expected to hold the largest share of this market in 2016, while Asia-Pacific is expected to grow at the fastest rate during the forecast period from 2016 to 2021. Improving healthcare infrastructure and favorable government initiatives in Asia-Pacific region is expected to drive the NGS market in this region.

Illumina, Inc. (U.S.); Thermo Fisher Scientific, Inc. (U.S.); Pacific Biosciences of California, Inc. (U.S.); Roche Holding AG (Switzerland); QIAGEN N. V. (Germany); BGI (China), Macrogen Inc. (South Korea); Eurofins Scientific (Luxembourg); and Oxford Nanopore Technologies, Ltd. (U.K.) are the key players in the global NGS market.